New agents for the treatment of cancer-related fatigue

Cancer

Volumn 92, Issue , 2001, Pages 1714-1718

  Burks, Thomas F ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMFEBUTAMONE; ANGIOGENESIS INHIBITOR; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; ANTISENSE OLIGONUCLEOTIDE; BRADYKININ ANTAGONIST; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DEXAMPHETAMINE; GINKGO BILOBA EXTRACT; HYDROCORTISONE; INFLIXIMAB; METHYLPHENIDATE; MODAFINIL; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PLATINUM DERIVATIVE; PREDNISONE; PSYCHOSTIMULANT AGENT; RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANEMIA; ARTHRITIS; CANCER; CANCER PATIENT; CONFERENCE PAPER; COPING BEHAVIOR; DEPRESSION; DIETARY INTAKE; EXERCISE; FATIGUE; HUMAN; HYDRATION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY;

ALPHA-MSH; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FATIGUE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PENTOXIFYLLINE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0035883527     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010915)92:6+<1714::AID-CNCR1502>3.0.CO;2-N     Document Type: Article

References (37)

1. Fatigue: Measures and relation to pain
2. Comparing patient, parent, and staff descriptions of fatigue in pediatric oncology patients
3. Resolving the frustration of fatigue
4. Fatigue in women receiving adjuvant chemotherapy for breast cancer: Characteristics, course, and correlates
5. Revealing response shift in longitudinal research on fatigue: The use of the thentest approach
6. Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation
7. Predictors of participant retention in two chemoprevention feasibility trials
8. The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue
9. Fatigue mediates the effects of exercise on quality of life
10. Drugs and sport: Research findings and limitations
11. An in-flight investigation of the efficacy of dextroamphetamine for sustaining helicopter pilot performance
12. Alerting effects of methylphenidate under basal and sleep-deprived conditions
13. The use of amphetamines in U.S. Air Force tactical operations during Desert Shield and Storm
14. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature
15. Alertness-enhancing drugs as a countermeasure to fatigue in irregular work hours
16. Chronopharmacokinetics and chronopharmacodynamics of dextroamphetamine in man
17. Neurosteroids: Biochemistry, modes of action, and clinical relevance
18. Low-dose hydrocortisone in chronic fatigue syndrome: A randomized crossover trial
19. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: A randomized controlled trial
20. Atypical antidepressants vs. imipramine in the treatment of major depression: A meta-analysis
21. Disturbed neuroendocrine-immune interactions in chronic fatigue syndrome
22. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health
23. Acute phase responses and cytokine secretion in chronic fatigue syndrome
24. Transforming growth factor-beta activated during exercise in brain depresses spontaneous motor activity of animals: Relevance to central fatigue
25. TNF-alpha and chronic fatigue syndrome
26. Effect of pentoxifylline and somatostatin on tumor necrosis factor production by human pulmonary macrophages
27. Cyclooxygenase-2 is required for tumor necrosis factor-alpha- and angiotensin II-mediated proliferation of vascular smooth muscle cells
28. Celecoxib: A review of its use in osteo-arthritis, rheumatoid arthritis and acute pain
29. Effects of pentoxifylline and nabumetone on the serum levels of IL-1 beta and TNF-alpha in rats with adjuvant arthritis
30. Rationalizing cyclooxygenase (COX) inhibition for maximal efficacy and minimal adverse events
31. Expression of cyclooxygenase (COX)-1 and COX-2 in adaptive cytoprotection induced by mild stress
32. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor
33. Molecular basis of the alpha-MSH/IL-1 antagonism
34. Immunotherapy of inflammatory bowel diseases: Current concepts and future perspectives
35. Cytokine blockade as a new strategy to treat rheumatoid arthritis: Inhibition of tumor necrosis factor
36. Structure activity relationships for bradykinin antagonists on the inhibition of cytokine release and the release of histamine
37. Antagonistic effects of Ginkgo biloba extract on adhesion of monocytes and neutrophils to cultured cerebral microvascular endothelial cells